Petta S - Search Results

1

Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (LISTEN): A double-blind randomised placebo-controlled trial.

Noto D, Petta S, Giammanco A, Spina R, Cabibbi D, Porcasi R, Caldarella R, Ciaccio M, Muratore R, Cefalù AB, Craxi A, Averna M. Noto D, et al. Among authors: petta s. Nutr Metab Cardiovasc Dis. 2022 May;32(5):1288-1291. doi: 10.1016/j.numecd.2022.01.024. Epub 2022 Jan 29. Nutr Metab Cardiovasc Dis. 2022. PMID: 35256232 Clinical Trial.

2

Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?

Lo Iacono O, Petta S, Venezia G, Di Marco V, Tarantino G, Barbaria F, Mineo C, De Lisi S, Almasio PL, Craxì A. Lo Iacono O, et al. Among authors: petta s. Am J Gastroenterol. 2005 Nov;100(11):2472-7. doi: 10.1111/j.1572-0241.2005.00244.x. Am J Gastroenterol. 2005. PMID: 16279902

3

The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C.

Lo Iacono O, Venezia G, Petta S, Mineo C, De Lisi S, Di Marco V, Rodolico V, Amato M, Ferraro D, Giordano C, Almasio PL, Craxí A. Lo Iacono O, et al. Among authors: petta s. Aliment Pharmacol Ther. 2007 May 15;25(10):1181-91. doi: 10.1111/j.1365-2036.2007.03309.x. Aliment Pharmacol Ther. 2007. PMID: 17451564 Free article.

4

Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection.

Petta S, Cammà C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, Craxì A. Petta S, et al. Am J Gastroenterol. 2008 May;103(5):1136-44. doi: 10.1111/j.1572-0241.2008.01813.x. Am J Gastroenterol. 2008. PMID: 18477344

5

Retinol-binding protein 4: a new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1.

Petta S, Cammà C, Di Marco V, Alessi N, Barbaria F, Cabibi D, Caldarella R, Ciminnisi S, Licata A, Massenti MF, Mazzola A, Tarantino G, Marchesini G, Craxì A. Petta S, et al. Hepatology. 2008 Jul;48(1):28-37. doi: 10.1002/hep.22316. Hepatology. 2008. PMID: 18506842

6

Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis.

Cammà C, Petta S, Di Marco V, Bronte F, Ciminnisi S, Licata G, Peralta S, Simone F, Marchesini G, Craxì A. Cammà C, et al. Among authors: petta s. Hepatology. 2009 Jan;49(1):195-203. doi: 10.1002/hep.22655. Hepatology. 2009. PMID: 19065558

7

Non-alcoholic fatty liver disease pathogenesis: the present and the future.

Petta S, Muratore C, Craxì A. Petta S, et al. Dig Liver Dis. 2009 Sep;41(9):615-25. doi: 10.1016/j.dld.2009.01.004. Epub 2009 Feb 14. Dig Liver Dis. 2009. PMID: 19223251 Review.

8

Hepatitis C and diabetes: the inevitable coincidence?

Lonardo A, Adinolfi LE, Petta S, Craxì A, Loria P. Lonardo A, et al. Among authors: petta s. Expert Rev Anti Infect Ther. 2009 Apr;7(3):293-308. doi: 10.1586/eri.09.3. Expert Rev Anti Infect Ther. 2009. PMID: 19344243 Review.

9

Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis.

Petta S, Cammà C, DI Marco V, Calvaruso V, Enea M, Bronte F, Butera G, Cabibi D, Craxì A. Petta S, et al. Aliment Pharmacol Ther. 2009 Sep 15;30(6):603-13. doi: 10.1111/j.1365-2036.2009.04079.x. Epub 2009 Jun 25. Aliment Pharmacol Ther. 2009. PMID: 19563503 Free article.

10

Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection.

Petta S, Cammà C, Di Marco V, Cabibi D, Ciminnisi S, Caldarella R, Licata A, Massenti MF, Marchesini G, Craxì A. Petta S, et al. Antivir Ther. 2009;14(5):631-9. Antivir Ther. 2009. PMID: 19704165

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

331 results

Search Page